Why the study?
Patients hospitalized for acutely decompensated chronic HF and de novo acute HF continue to experience unacceptably high post-discharge readmission and mortality rates.
Does the use of SGLT2 inhibitors improve clinical outcomes in patients hospitalized for acute heart failure?
Does the use of SGLT2 inhibitors improve clinical outcomes in patients hospitalized for acute heart failure?
Answers are grounded in this paper and cite their sources.
This review highlights the utility of SGLT2 inhibitors in improving outcomes for patients hospitalized with acute heart failure.
AIMS: Heart failure (HF) is the most frequent cause of hospital admission among patients 65 years or older. Patients hospitalized for acutely decompensated chronic HF and 'de novo' acute heart failure (AHF) continue to experience unacceptably high post-discharge readmission and mortality rates. METHODS AND RESULTS: Until recently, trials had failed to improve outcome in patients with AHF irrespective of ejection fraction with exception of sodium-glucose co-transporter 2 inhibitors (SGLT2i) that improved clinical outcomes in patients hospitalized for AHF in the Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure (EMPULSE) and in the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials. CONCLUSIONS: This document reviews the potential utility of SGLT2i in patients hospitalized for AHF.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: